Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease / Fiorino, G., Ruiz-Arguello, M.b., Maguregui, A., Nagore, D., Correale, C., Radice, S., Gilardi, D., Allocca, M., Furfaro, F., Martinez, A., Danese, S.. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 24:3(2018), pp. 601-606. [10.1093/ibd/izx086]